<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856478</url>
  </required_header>
  <id_info>
    <org_study_id>1200.161</org_study_id>
    <nct_id>NCT01856478</nct_id>
  </id_info>
  <brief_title>LUX-Head&amp;Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy</brief_title>
  <official_title>A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This randomized, open-label, phase III study will be performed in patients with recurrent
      and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The
      objectives of this trial are to compare the efficacy and safety of afatinib versus
      methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 23, 2013</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS), defined as the time from the date of randomization to the date of progression evaluated according to RECIST 1.1 or to the date of death, whichever occurs first</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), defined as the time from the date of randomization to the date of death (regardless of the cause of death)</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response defined as complete response (CR) or partial response (PR) determined by RECIST 1.1 according to the best response to study medication</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (HRQOL) will be assessed based on patient-reported questionaires</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral intake, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous bolus injection, once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>intravenous bolus injection, once weekly</description>
    <arm_group_label>methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>oral intake, once daily</description>
    <arm_group_label>afatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity,
             oropharynx, hypopharynx or larynx, which has recurred/metastasised and is not amenable
             for salvage surgery or radiotherapy.

          -  Documented progressive disease based on investigator assessment according to RECIST,
             following receipt of a cisplatin and/or carboplatin and/or Nedaplatin based regimen
             administered for recurrent and/or metastatic disease independent of whether patient
             progressed during or after platinum based therapy.

          -  Measurable disease according to RECIST (version 1.1).

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at Visit 2.

          -  Male and female patients age is 18 years or older

          -  Signed and dated written informed consent that is in compliance with ICH-GCP and local
             law.

        Exclusion criteria:

          -  Progressive disease within three months after completion of curatively intended
             treatment for locoregionally advanced or for metastatic head and neck squamous cell
             cancer (HNSCC).

          -  Primary tumour site nasopharynx (of any histology), sinuses, and/or salivary glands.

          -  Any other than one previous platinum based systemic regimen given for recurrent and/or
             metastatic disease, with the exception of immunotherapy used either before or after
             platinum based treatment. Re-challenge with the platinum based regimen after a
             temporary break is considered an additional line regimen only in case of progression
             within the break.

          -  Prior treatment with EGFR-targeted small molecules.

          -  Treatment with any investigational drug less than four weeks or anti-cancer therapy
             less than three weeks prior to randomization (except palliative radiotherapy to bones
             to alleviate pain).

          -  Unresolved chronic toxicity, other than hearing loss, tinnitus or dry mouth, CTCAE
             grade &gt;2 from previous anti-cancer therapy or unresolved skin toxicities CTCAE grade
             &gt;1 and/or diarrhoea CTCAE grade &gt;1 caused by prior treatment with EGFR targeted
             antibodies.

          -  Previous tumour bleeding CTCAE grade =3.

          -  Requirement for treatment with any of the prohibited concomitant medications.

          -  Major surgical or planned procedure less than four weeks prior to randomization
             (isolated biopsies are not considered as major surgical procedures).

          -  Any other malignancy unless free of disease for at least five years except for:

               -  Other HNSCC of a location as described in inclusion criterion number 1

               -  Appropriately treated superficial basal cell skin cancer

               -  Surgically cured cervical cancer in situ

               -  For Korea: endoscopically cured superficial esophageal and/or gastric cancer is
                  allowed

          -  Known lesion or signs of brain metastasis.

          -  Known pre-existing interstitial lung disease (ILD).

          -  Clinically relevant cardiovascular abnormalities, as judged by the investigator, such
             as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA
             classification =III, unstable angina, myocardial infarction within six months prior to
             randomization, or poorly controlled arrhythmia.

          -  Significant or recent acute gastrointestinal disorders with diarrhoea as a major
             symptom in the opinion of the investigator, e.g. Crohn's disease, malabsorption or
             CTCAE grade &gt;1 diarrhoea of any aetiology at randomization.

          -  Known HIV, active hepatitis B, active hepatitis C, and/or other known severe
             infections, including but not limited to tuberculosis, as judged by the investigator.

          -  Other significant disease that in the investigator's opinion would exclude the subject
             from the trial.

          -  Screening laboratory values:

               -  Absolute neutrophil count (ANC) &lt;1.5x10^9/l

               -  Platelet count &lt;75x10^9/l

               -  Total bilirubin &gt;1.5 times the upper limit of normal (ULN)

               -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) &gt;3 times the
                  ULN (if related to liver metastases &gt;5 times the ULN)

               -  Calculated creatinine clearance &lt;50 ml/min (as evidenced by using the
                  Cockcroft-Gault formula).

          -  Women of child-bearing potential and men who are able to father a child, unwilling to
             be abstinent or to use adequate contraception during the trial and for at least six
             months after end of treatment. Adequate methods of contraception and definition of
             child-bearing potential.

          -  Pregnancy or breast feeding.

          -  Known or suspected hypersensitivity to any of the study medications or their
             excipients.

          -  Patients unable to comply with the protocol, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated toumor hospital of bengbu medical college</name>
      <address>
        <city>Bengbu</city>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Sichuan</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Haerbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the 81th Hospital of PLA</name>
      <address>
        <city>Nanjing</city>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital of Shanghai Second Medical University</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200125</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandria University Hospital</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute, Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansoura University Faculty of Medicine</name>
      <address>
        <city>Dakahlia</city>
        <zip>324</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sujan Surgical Cancer Hospital</name>
      <address>
        <city>Amravati</city>
        <zip>444606</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pristine Hospital</name>
      <address>
        <city>Bengaluru</city>
        <zip>560086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acharya Tulsi Regional Cancer Treatment &amp; Research Institute</name>
      <address>
        <city>Bikaner</city>
        <zip>334001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Government General Hospital</name>
      <address>
        <city>Chennai</city>
        <zip>600003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M N J Institute of Oncology and Regional Cancer Centre</name>
      <address>
        <city>Hyderabad</city>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geetanjali Medical College and Hospital</name>
      <address>
        <city>Jaipur</city>
        <zip>313002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J K Cancer Institute</name>
      <address>
        <city>Kanpur</city>
        <zip>208005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B. P .Poddar Hospital &amp; Medical Research Ltd.</name>
      <address>
        <city>Kolkata, West Bengal</city>
        <zip>700053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Medical University</name>
      <address>
        <city>Lucknow</city>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College &amp; Hospital</name>
      <address>
        <city>Nagpur</city>
        <zip>440009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Hospital, Nashik</name>
      <address>
        <city>Nasik</city>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noble Hospital Pvt Ltd</name>
      <address>
        <city>Pune</city>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital (Cebu)</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Lover's Lake Branch</name>
      <address>
        <city>Keelung City</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Muang</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naresuan University Hospital</name>
      <address>
        <city>Phitsanulok</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Egypt</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

